American Journal of Medicine and Medical Sciences 2024, 14(4): 1051-1059
DOI: 10.5923/j.ajmms.20241404.52

Methods of Modeling Experimental Coagulopathy: A Bibliographic Review

Yunuskhodjaev Akhmadkhodja[1], Akromova Makhfuza[1], Saidov Saidamir[1], Mirsultanov Jakhongir[1], Akhmedova Dilafruz[2], Akhmedov Dilshod[3]

[1]Institute of Pharmaceutical Education and Research, Tashkent, Uzbekistan
[2]Tashkent Medical Academy, Tashkent, Uzbekistan
[3]Center for Pulmonology and Phthisiology, Tashkent, Uzbekistan

Abstract Coagulopathy, a complex disorder involving abnormalities in blood clotting mechanisms, poses significant challenges in both clinical management and research. Understanding the intricate interplay of various factors contributing to coagulopathy requires robust experimental models. This bibliographic review aims to provide insights into the diverse methods utilized in modeling experimental coagulopathy. Through an extensive examination of existing literature, this review discusses the spectrum of approaches employed in inducing coagulopathic conditions, including trauma-induced coagulopathy, disseminated intravascular coagulation, and drug-induced coagulopathy, among others. Furthermore, it explores the diverse animal models utilized, ranging from rodents to larger mammals, each offering unique advantages and limitations. Methodologies such as ex vivo assays, in vivo imaging techniques, and molecular analyses are also evaluated for their utility in elucidating the underlying mechanisms of coagulopathy. Moreover, this review addresses the importance of outcome measures in assessing coagulation abnormalities, emphasizing the need for standardized endpoints to facilitate comparability across studies. By critically analyzing the strengths and limitations of different modeling approaches, this review provides valuable insights for researchers seeking to advance our understanding of coagulopathy and develop novel therapeutic strategies.

Keywords Coagulopathy, Experimental models, Bibliographic review, Trauma-induced coagulopathy, Disseminated intravascular coagulation

1. Introduction

Coagulopathy, a multifaceted disorder characterized by abnormalities in blood clotting mechanisms, presents significant challenges in both clinical management and research endeavors. The intricate interplay of various factors contributing to coagulopathy necessitates robust experimental models that can accurately mimic the complexities observed in clinical settings. These models serve as invaluable tools for elucidating underlying pathophysiological mechanisms, exploring potential therapeutic interventions, and evaluating novel diagnostic approaches [1,2,3,4].

In recent years, there has been a surge in research focused on developing and refining experimental models of coagulopathy. These models encompass a broad spectrum of conditions, including trauma-induced coagulopathy, disseminated intravascular coagulation (DIC), drug-induced coagulopathy, and various congenital or acquired coagulation disorders. Each of these conditions presents unique challenges, requiring tailored approaches to effectively mimic the associated pathophysiology [5].

Animal models have long been instrumental in studying coagulopathy, offering the ability to manipulate variables, control environmental factors, and observe physiological responses in a controlled setting. From rodent models to larger mammalian species, each animal model brings its own set of advantages and limitations, influencing the choice of model based on the specific research question and experimental objectives [6,7,8].

Furthermore, advancements in research methodologies have expanded the repertoire of tools available for studying coagulopathy. Ex vivo assays, such as thromboelastography (TEG) and rotational thromboelastometry (ROTEM), provide valuable insights into the dynamic properties of blood clot formation and dissolution. In vivo imaging techniques, molecular analyses, and genetic manipulations offer deeper mechanistic insights into the underlying pathophysiology of coagulopathy [9].

Despite the diversity of experimental models and methodologies available, there remains a need for standardization and harmonization to facilitate comparability across studies. Standardized endpoints and outcome measures are essential for meaningful interpretation of results and

Received: Mar. 20, 2024; Accepted: Apr. 9, 2024; Published: Apr. 19, 2024
Published online at http://journal.sapub.org/ajmms

translational relevance to clinical practice [10,11].

In this bibliographic review, we aim to provide a comprehensive overview of the methods utilized in modeling experimental coagulopathy. By critically evaluating existing literature, we will discuss the strengths and limitations of different modeling approaches, explore the utility of various animal models and research methodologies, and highlight emerging trends and future directions in the field. Ultimately, this review aims to contribute to the advancement of our understanding of coagulopathy and the development of effective therapeutic strategies to address this challenging clinical condition [12,13,14].

Warm harm is related with critical dismalness and mortality and is one of the under-recognized causes of harm [15,16]. This sort of harm has critical socio-economic results that influence all social bunches of the populace. Hence, within the world, burns occupy third put within the structure of all outside causes of passing, along with poisoning and suicide [15,16,17]. Each year, roughly 11 million individuals require hospitalization due to warm harm [16]. Within the USA, approximately 500,000 cases of burn damage, 40 thousand hospitalizations and almost 5 thousand passings are enlisted every year [16,17]. In center- and low-income nations, the anticipated mortality from burn damage is 180,000 cases per year [16]. In Russia, from 294.2 to 384 cases of warm harm per 100,000 populaces are enlisted yearly [18], in 2016, the bunch of patients with an influenced region of 30% of the body surface or more produced to around 3.2 thousand patients, and the mortality rate from warm harm was almost 1.5 thousand cases [18]. Within the Republic of Belarus, almost 30 thousand cases of burn wounds, 9 thousand hospitalizations and almost 350 passings are enrolled yearly [17]. In terms of the level of inability, budgetary costs for treating patients and restoring convalescents, burns possess 1st put among all sorts of wounds [19]. The coordinate financial burden ranges from 10.5 million euros (Norway, 2007) to 1 billion dollars per year (USA, 2000), not counting circuitous costs of disability and restoration [16,21]. The normal cost of hospitalization for a quiet with warm damage is $17,600 [22]. In Russia, the normal taken a toll of treating a quiet with a serious burn damage ranges from 201,960 to 250,433 rubles. rub. [23]. Extreme warm damage leads to the advancement of burn illness, which is went with by brokenness of different organs and frameworks, resistant and fiery responses, metabolic changes and distributive stun, which can lead to numerous organ disappointment and passing [15,24,25]. One of the complications of burn illness is systemic coagulopathy. Coagulation changes depicted in patients with serious burns are comparative to those watched in patients with sepsis or extreme injury, but have a number of highlights [26]. Since the event of coagulopathy in patients with serious burns has been portrayed as a hazard figure for expanded dismalness and mortality early after burns, as well as afterward within the clinical course [26,27], coagulopathy can be considered as a potential helpful target. There are right now no clear rules for the treatment of coagulopathy in patients with serious burns, so advance ponder of this wonder is promising [26].

2. Purpose of the Research

The purpose of this bibliographic review is to comprehensively explore and evaluate the various methods used in modeling experimental coagulopathy. Coagulopathy represents a complex and multifaceted disorder with significant clinical implications, including increased morbidity and mortality rates. Understanding the pathophysiological mechanisms underlying coagulopathy and developing effective therapeutic interventions necessitates robust experimental models that accurately recapitulate the complexities observed in clinical settings.

Through this review, we aim to achieve several specific objectives:

Surveying Existing Literature: We will conduct a thorough examination of the existing literature to identify and analyze the diverse methods utilized in experimental coagulopathy modeling. This includes investigating the spectrum of conditions modeled, such as trauma-induced coagulopathy, disseminated intravascular coagulation (DIC), drug-induced coagulopathy, and congenital or acquired coagulation disorders.

Evaluation of Animal Models: We will assess the utility of different animal models, ranging from rodents to larger mammalian species, in modeling coagulopathy. This evaluation will encompass considerations such as species-specific physiological characteristics, feasibility, and translational relevance to human pathology.

Analysis of Research Methodologies: We will explore the array of research methodologies employed in coagulopathy modeling, including ex vivo assays, in vivo imaging techniques, molecular analyses, and genetic manipulations. By critically evaluating the strengths and limitations of these methodologies, we aim to provide insights into their utility in elucidating the underlying mechanisms of coagulopathy.

By achieving these objectives, this bibliographic review aims to provide researchers and clinicians with a comprehensive overview of the methods used in modeling experimental coagulopathy, ultimately contributing to the development of effective therapeutic strategies and improved clinical management of this challenging disorder.

3. Materials and Methods

Literature Search Strategy: A systematic literature search will be conducted using electronic databases such as PubMed /MEDLINE, Scopus, Web of Science, and Google Scholar. The search strategy will involve using relevant keywords and Medical Subject Headings (MeSH) terms related to experimental coagulopathy, animal models, research methodologies, and outcome measures. The search will be limited to articles published in English, with no restrictions on publication date.

By employing these methods, the review aims to provide a comprehensive and rigorous analysis of the methods used in modeling experimental coagulopathy, contributing to advancements in the field and informing future research directions.

35 scientific articles were studied and analyzed in the databases PubMed, Google Scholar, ScienceDirect, RSCI for the period from 1993 to 2021, which provide data on the epidemiology, clinical picture, prevention and treatment of coagulopathies in patients with burn injury. The time interval of the scientific articles studied is due to the generally small number of publications on this topic. The review included randomized controlled trials, systematic reviews, multi-/single-centre studies and meta-analyses. Search terms included: "burns," "coagulation disorders," "coagulopathy," "hemostasis," and "burn-induced coagulopathy." When preparing the review, PRISMA recommendations were used [20].

4. Main Section

To understand the dynamic changes in the coagulation and anticoagulation systems, as well as the development of dysfunction of these systems, it is necessary to recall the basic principles of the modern concept of the functioning of the hemostatic system. There are two main mechanisms for the initiation of coagulation: the extrinsic pathway (production of tissue factor (TF)) and the intrinsic pathway (the effect on the coagulation system of factors that can support the autoactivation of factor XII) [28,29,30]. Activation of the coagulation cascade along the extrinsic pathway occurs through two main mechanisms: the release of TF into the bloodstream upon contact of blood plasma with extravascular cells, such as smooth muscle cells and fibroblasts (which constitutively express TF on their surface), and intravascular expression of TF on the surface of leukocytes (monocytes) and/or endothelial cells in response to agonists (ie, inflammatory cytokines). In the first case, the effect of TF occurs simultaneously with the effect of extracellular matrix proteins, which cause platelet adhesion/activation, thereby localizing platelets and TF at the site of injury [28]. Triggering of the cascade along the intrinsic pathway is based on the release of foreign material into the blood (for example, in sepsis and other conditions) and the presence of intracellular material (for example, DNA histones) due to physical destruction of cells or the induction of apoptosis [30,31]. Activation of the hemostatic system through extravascular TF is necessary for local initiation of the coagulation system upon vessel injury in order to form and maintain a physical barrier (fibrin/platelet clot) that restores the barrier between the circulatory system and the extravascular space. In contrast, the presence of clotting initiators in the circulating blood, whether molecules that trigger FXII activation or intravascular cells expressing TF, is often due to the consequences of injury or other pathology [28,29,30,31]. A key factor in the response to vascular injury is the enzyme thrombin. This enzyme exhibits procoagulant, anticoagulant, antifibrinolytic and cellular effects [28]. Key roles of thrombin in the initial phase of the response to vascular injury include: formation of fibrin from fibrinogen; platelet activation; activation of FXIII (combines fibrin subunits, improving the mechanical stability of the fibrin matrix); activation of thrombin-activated fibrinolysis inhibitor (TAFI), a carboxypeptidase that modifies fibrin, increasing its resistance to lysis [28,29,30,31]. Negative regulation of the coagulation response is primarily mediated by the activity of tissue factor pathway inhibitor (TFPI), AT, protein S (PS), and protein C (PC). Together, these factors provide a threshold-limited response system in which a stimulus of sufficient strength must be provided to continue the response. TFPI is a multivalent inhibitor of the FVIIa-TF complex. TFPI inhibits the FVIIa-TF complex in an FXa-dependent manner and is the primary regulator of the initiation phase of thrombin formation.

AT could be a part of the serpin proteinase inhibitor family and forms irreversible complexes with most proteinases included within the coagulation response, counting thrombin, FXa, FIXa, TF-FVIIa and FXIa. AT is the most inhibitor of thrombin, and its lack is related with expanded thromboembolic complications [28,29,30,31]. PS acts as an inhibitory cofactor and upgrades the viability of TFPI and PC. PC is basically dependable for hindering the transformation of prothrombin to thrombin, and in like manner, PC and PC insufficiency are related with an expanded chance of thrombosis [16]. Key components of the PC pathway incorporate two proteins expressed on the luminal surface of endothelial cells: thrombomodulin (TM), which ties thrombin to create the PCase complex, a compelling catalyst for the change of PC to actuated PC, and the endothelial cell PC receptor, which conveys PC to the thrombin complex. -TM [16]. Ponders demonstrate that PC enactment leads to the shutdown of the FV/FVa and FVIII/FVIIIa complexes. PC actuation could be a central energetic anticoagulant instrument that limits thrombus arrangement at the location of harm [28,29,30]. The arrangement of fibrin leads to the dispatch of an extra – fibrinolytic – framework, which plays a critical part in stifling the physical extension of the clot and within the last rebuilding of the structure and keenness of blood vessels [30]. The key components of the fibrinolytic framework are: plasminogen, t-PA (tissue plasminogen activator), which catalyzes the transformation of plasminogen to plasmin, PAI-1 (plasminogen activator inhibitor 1), the essential plasma inhibitor of t-PA; alpha-2-antiplasmin (AP), the most plasma inhibitor of plasmin; TAFI, which in its enacted frame hinders the actuation of plasminogen on the surface of fibrin. The fibrin component of the blood clot acts as a cofactor for plasminogen enactment by t-PA, coming about in effective plasmin generation as it were at the location of fibrin deposition [28,29,30]. However, the coagulation and anticoagulation frameworks don't exist in confinement and are affected by common body responses, such as the incendiary reaction. The fiery handle and coagulation have a complex framework of associations through the initiated expression of TF. In this way, interleukin-6 (IL-6) and

interleukin-8 (IL-8) increase the expression of monocyte TF in vitro, and provocative cytokines such as interleukin-1 (IL-1) and tumor rot factor-α (TNF-α), initiate the connection of microparticles carrying TF from monocytes to the surface of the endothelium. A think about of endotoxemia in people appeared that TF mRNA expression expanded 100-fold after LPS administration [27,32]. An increase within the level of TF mRNA is closely related with an increment in the thrombin-antithrombin complex (TAT) and prothrombin part, which demonstrates a resulting increment in thrombin movement [27,32]. The provocative prepare moreover invigorates coagulation by repressing fibrinolysis. PAI-1 is invigorated by IL-6 and TNF-α, making a difference to restrain fibrinolysis [27]. In expansion, concealment of TM and PC through the activity of IL-1 and TNF-α may advance the spread of coagulation past the specifically harmed tissue [32]. With an add up to burn zone of more than 15–20% of the body surface and/or profound burns of more than 10% of the body surface, a complex set of interrelated pathophysiological responses and systemic clinical signs creates in reaction to burn harm to the skin and fundamental tissues, called "burn disease." Amid this obsessive prepare, a number of progressive stages are recognized: burn stun (depending on the seriousness of the harm keeps going 2–4 days), burn toxemia (10–12 days from the minute of harm), septicotoxemia and irresistible complications, recuperation or burn depletion [25]. Within the to begin with 48 hours, patients with extreme burn harm create burn stun, which alludes to traumatic hypovolemic stun and incorporates components of distributive and cardiogenic shock [33]. Burn shock is characterized by a diffuse disorder of expanded vascular penetrability, in which misfortune of proteins, electrolytes and plasma happens, which leads to an extra diminish in intravascular volume, weakening of target organ perfusion and the improvement of cellular dysoxia (distorted cellular oxygen digestion system) [33,34]. Burn injury also enacts the coagulation cascade and the resistant framework, expanding the disturbance of large scale- and microcirculation.

The provocative reaction leads to endothelial harm, increments vascular spillage disorder and causes extreme coagulopathy [33,41]. Amid this period, a clutter of hemostasis creates, called intense burn coagulopathy (AOC), or burn-induced coagulopathy (IIC) [31,40]. Brokenness of the coagulation framework amid burn stun is characterized by actuation of procoagulation pathways, improved fibrinolytic movement and impeded movement of normal anticoagulants, and these changes depend relatively on the range of the burn and the profundity of the injury [27,35,37,38,39]. The pathogenesis of AIC in patients with serious burns is multifactorial, as a few pathophysiological components, separately or in combination, can initiate or disturb coagulopathy [37,31]. The primary of these is enactment of the outward pathway through the activity or release of TF. Typically affirmed by the watched proportionality between the seriousness of coagulopathy and the seriousness of burns [27,31,36,41]. The advancement of hyperinflammatory disorder in patients with severe burn harm may too serve as a critical pathophysiological figure within the enactment of the coagulation framework. Extreme burn damage actuates both a nearby provocative reaction of coagulative corruption and a systemic provocative reaction auxiliary to circulating cytokines [28,36,47]. The starting recede stage of hypermetabolic disorder, which creates amid the primary 1–3 days after warm harm, is characterized by diminished tissue perfusion and a transitory diminish in metabolic rate, comparative to the short-term fight-or-flight reaction [44]. Within the to begin with 24 hours, levels of IL-1, IL-6, IL-12, TNF-α and other fiery cytokines increase, and their levels connect with mortality within the to begin with 48 hours [21,42,44]. A number of considers appear that hyperinflammatory disorder, particularly expanded levels of IL-6, IL-8, TNF-α among other cytokines, shifts the hemostatic adjust towards coagulation [28]. Be that as it may, the relationship between the hyperinflammatory disorder in severe thermal harm and its impact on OOC isn't well caught on. Another critical pathophysiological component is hypoperfusion [31,42,45]. A critical include of burn stun is plasma loss that advances over time, outpacing the misfortune of cellular components. This makes it conceivable to preserve central hemodynamics at the level of emolument and subcompensation due to the centralization of hemodynamics and the mobilization of interstitial liquid into the vascular bed, in any case, indeed amid this period, with clear brief well-being, extreme metabolic disarranges develop in fringe tissues [45]. Tissue hypoperfusion leads to anaerobic digestion system, acidemia and lactic acidemia [31]. Hypothermia is critical within the improvement of coagulopathy. In patients with severe thermal damage, three periods of hypothermia are communicated:t the prehospital organize, amid surgery and within the postoperative period [48,49]. As burned patients lose their essential thermoregulatory boundary, they have a decreased capacity to preserve temperature homeostasis [44].

Hypothermia from heat loss through wounds is aggravated by massive infusion of room temperature solutions [31,45]. Patients often have a combination of severe burn injury and thermal inhalation injury, which also contributes to the development of coagulopathy [47]. The care of patients with severe burn injury differs markedly from the care of other trauma patients due to multiple factors (extensive fluid resuscitation, inhalation trauma, and skin dysfunction). Taking into account massive infusion therapy, as well as the different incidence of OOC, researchers came to the conclusion that hemodelution is a significant pathogenetic factor in the development of coagulopathy in patients with severe burn injury [31,41,44]. Together, coagulopathy, hypothermia (a decrease in body temperature to 35.5℃ or less) and acidemia (pH less than 7.25) are called the "deadly triad". The presence of the "deadly triad" in severely burned patients leads to a significant increase in mortality [31,44,50]. Thus, in the first 48 hours from the moment of injury, the hemostatic system is affected by a whole complex of pathogenetic factors, leading to disruption of the functioning of this system and the development of coagulopathy. Let us

consider in detail the known changes in the main components of the hemostatic system. Procoagulant factors in AOC in the vast majority of cases, platelet levels remain unchanged during acute thermal injury [28]. However, research data on platelet levels in the early period of severe thermal injury are conflicting. Thus, there are studies that indicate that platelet counts are elevated already on admission in patients with thermal injury [28,41], which may reflect variability in the time to measurement after injury. It has been suggested that intravascular hemolysis and red blood cell fragmentation may lead to pseudothrombocytosis, which may occur early [50]. The increasing use of viscoelastic measurements shows that when platelet counts are normal, platelet function is reduced [28]. Fibrinogen levels increase in the first 48 hours after burn injury [28,44]. The level of thrombin-antithrombin complex (TAC) increases immediately after a burn and reaches a peak within 48 hours [27,35,16]. Moreover, TAK levels correlate with injury severity and outcome [28]. An increase in TAK levels in the first 48 hours after a burn indicates ongoing systemic thrombin generation. FV levels remain normal during the first 48 hours after injury [28]. This suggests that the observed increase in thrombin generation is not significant enough to reduce FV levels. In addition, this may indicate an underlying difference in the mechanisms underlying the risk of bleeding between thermal and mechanical trauma. Thus, in traumatic coagulopathy, a decrease in FV levels is observed due to APC-mediated proteolysis [51]. FVIIa activity is elevated in the first 48 hours after thermal injury and correlates with injury severity and prognosis [40]. FVIII increases rapidly within the first 48 hours and remains above normal values until 40 days after injury [52,57]. Importantly, FVIII accumulates in endothelial Wiebel–Palade cells along with von Willebrand factor (VWF), and exocytosis of FWF into the vascular lumen is an important component of primary hemostasis in response to damage to the vascular endothelium [28]. Anticoagulant system in OOC Changes in the levels of endogenous anticoagulants are better described in the literature than the state of the procoagulant system. In severe thermal injury, antithrombin (AT), protein C (PC), and protein S (PS) levels decrease during the first 48 hours after injury, while soluble TM and TFPI levels increase or remain at normal levels [52]. AT is a major inhibitor of key coagulation enzymes, including thrombin and FXa. Thus, a decrease in AT levels reflects a decrease in the ability to suppress coagulation. Within 48 hours after a burn injury, a noticeable decrease in AT levels is observed [35,52]. PC and PS are key components of the anticoagulant system. Concentrations of PC and PS decrease immediately after thermal injury [28,31]. Loss of both PC and PS after burn injury results in a concomitant decrease in the ability to suppress coagulation with a potentially increased risk of thrombosis and decreased inhibition of inflammation [52]. TM is a transmembrane glycoprotein expressed on the luminal surface of endothelial cells [28].

It capacities as a high-affinity receptor for thrombin, and the coming about complex is the most physiological activator of PC. Evaluation of TM after damage more often than not depends on the estimation of parts discharged by proteolysis of the extracellular space of TM [52], measured as dissolvable TM. In a rabbit burn demonstrate, warm harm was found to initiate the discharge of TM from the endothelium [28,31], successfully canceling its anticoagulant part in PC enactment. In patients with serious warm harm, plasma TM levels increment inside 48 hours after damage [28]. Taken together, this shows that during severe warm damage, there's enactment or harm to the endothelium, which leads to the separation of HM from the endothelium and an increment in broken down HM. Warm harm to the skin and movement of the stasis zone within the early period after harm contributes to a hypercoagulable state due to TM proteolysis. A comparable increment in dissolvable HM is watched in traumatic coagulopathy [52]. The fibrinolysis framework in OOC After a burn damage, the action and concentration of profibrinolytic chemicals increment. The foremost frequently centered on tissue plasminogen activator (t-PA) and plasminogen. The concentration of t-PA increments within the intense stage of burn damage [28,25]. Plasminogen levels diminish promptly after warm damage and are relative to the severity of the damage [28]. In spite of the quick increment in profibrinolytic movement after burn damage, an increment in antifibrinolytic variables is additionally watched. Plasminogen activator inhibitor 1 (PAI-1) and alpha-2-antiplasmin (AP) are the foremost broadly examined inhibitors of fibrinolysis. PAI-1 ties to t-PA and urokinase plasminogen activator (u-PA) to anticipate the change of plasminogen to plasmin [31]. PAI-1 levels increment and reach a crest instantly after burn harm, at that point the concentration diminishes to ordinary or near-normal levels [28,31]. Immediate post-burn concealment of fibrinolysis may be vital to preserve coagulation homeostasis after warm harm, but auxiliary actuation of the fibrinolytic framework in reaction to fibrin testimony can lead to a paradoxical state of hypofibrinolysis coexisting with focused on fibrinolysis [52]. Hence, in the primary 48 to 72 hours, patients with serious warm damage involvement a net increment in procoagulant potential. Considers of components of the fibrinolytic cascade show both hyper- and hypofibrinolysis. Whether these changes are portion of a broader marvel special to burn injury or or maybe portion of a common reaction to damage is hazy [21]. Caution ought to be worked out when endeavoring to decide hyper- or hypocoagulable status based exclusively on levels of person markers. Considers illustrate the acceptance of both conditions within the early period of burn malady [28,54]. Early recognizable proof of coagulation clutters in patients with burn malady can be challenging. Evaluating particular coagulation markers is usually time expending and nearly continuously costly, whereas schedule research facility coagulation tests such as INR and APTT have restricted demonstrative esteem. The need of clear definitions or demonstrative criteria for coagulopathy, as well as the need of basic and effectively translated demonstrative tests, may darken the discovery rate of coagulopathy in patients with extreme burns. Standardizing the definition of

coagulopathy and getting a higher battery of demonstrative tests may be the primary step toward better understanding the genuine rate of coagulopathy in these patients. Hence, there's a have to be recognize potential variables that decide the inclination of patients to hyper- or hypocoagulation among demographic characteristics, harm characteristics, clinical and research facility investigate strategies, standard coagulogram markers, biochemical markers of inflammation, and standard thromboelastogram pointers. As before long as the persistent encounters burn stun (48–72 hours), a period starts when the drawn out presence of hypermetabolic disorder, seriously care and surgical treatment [61], and the advancement of irresistible complications have a critical affect on the patient's encourage condition. At the same time, the levels of a few of the coagulation components that increment amid burn stun stay strangely lifted or diminished. Amid this period, dynamic surgical treatment starts (necrectomy and plastic closure of wound abandons). The capacity to form and keep up a thrombus plays a key part within the capacity to perform surgical treatment. Hypermetabolic disorder holds on after burn stun [17,44].

After the acute phase, a hypermetabolic "flow" phase begins, characterized by increased perfusion of superficial tissues, high levels of adrenaline, glucocorticoids and increased levels of inflammatory cytokines. There is a correlation between high levels of IL-1, IL-6, IL-10, IL-12 and TNF-α in plasma 1 week after burn injury and deaths [21,44]. The release of catecholamines stimulates platelet aggregation [8]. On the 10th–12th day after a burn injury, a period of purulent-septic complications, including septic ones, develops. Sepsis is a common complication in patients with severe burns, and sepsis-induced coagulopathy (SIC) may also cause or worsen existing coagulopathy in patients with severe burns [15,45,57]. Activation of the coagulation system and subsequent thrombus formation occurs in most patients with sepsis [57]. Approximately half of all patients with sepsis have disseminated intravascular coagulation (DIC) [57]. During SIC, both blood cells and vascular endothelial cells, as well as coagulation factors, play a key role. The blood coagulation cascade is initiated by the expression of TF on monocytes, platelets, endothelial cells and, possibly, neutrophils [57]. A complex consisting of TF and factor VIIa catalyzes the conversion of inactive FX into its active form, which leads to further activation of blood coagulation [57]. Due to the development of hypermetabolic syndrome and the addition of infectious complications, the levels of cytokines in patients with burn injury differ significantly from the levels in healthy patients. Cytokines produced by leukocytes in response to infectious processes stimulate the expression of TF and subsequent activation of coagulation. Thus, IL-6 can initiate TF expression in mononuclear cells, and inhibition of this cytokine can block TF-dependent thrombin generation [44–58]. TNF-α, a cytokine produced by blood monocytes and tissue macrophages under conditions of endotoxemia and inflammation, can stimulate TF expression in several cell lines, including endothelium. Also, TNF-a can simultaneously inhibit anticoagulant PC and PS [32]. These pathways are driven by monocyte stimulation and cytokine release in response to TF-FVIIa protease-activating receptor (PAR) 2 binding, which stimulates the release of IL-6 and IL-8 [44–49]. Similarly, PAR receptors 1, 3 and 4, found on platelets, endothelium, leukocytes and many other cells, bind thrombin and other clotting factors. This leads to further platelet and endothelial cell activation, neutrophil infiltration and cytokine release [46]. The complement system, in response to infectious stimuli, is activated by several mechanisms and represents another point of connection between inflammation and coagulation. The complement system can be activated by antibodies to bacterial elements, endotoxins, or direct contact with bacteria. Once activated, complement factors can affect the coagulation system through several mechanisms. The terminal complement complex (TCC) can activate the endothelium, providing a surface that promotes clot formation [44]. Activated alternative pathway C3 can activate platelets and promote aggregation. Similarly, activated C5 stimulates a wide range of inflammatory and endothelial cells to induce TF expression. Complement causes clots to form in a variety of ways in response to invading microbes. However, the blood coagulation system, when activated, can also affect components of the complement system. Thrombin is a potent activator of C5 leading to subsequent TCC formation. Plasmin, the final enzyme in fibrin clot degradation, can activate both C5 and C3. Other serine proteases in coagulation cascades also activate complement, including FIXa, FXa, FXIa and FXIIa [30]. Neutrophil activation plays an important role in SIC. First, activated neutrophils present TF in significant quantities. Activation of neutrophils can occur either in response to direct interaction with microorganisms (neutrophils phagocytose a foreign body) or through activation by small molecules released by damaged cells or bacteria. Neutrophils, in response to activation, release elastase, which inhibits plasminogen by cleavage. Moreover, neutrophil elastase inhibits an important suppressor of the coagulation system, an inhibitor of the TF pathway. The greatest contribution of neutrophils to immunothrombosis occurs through their ability to release neutrophil extracellular traps (NETs).

These nets, as the title recommends, offer assistance in catching and expelling microorganisms. NETs contain critical sums of DNA and different proteins, counting histones and antimicrobial proteins, which offer assistance trap and neutralize microscopic organisms. Systems moreover straightforwardly and in a roundabout way impact coagulation. Extracellular DNA, frequently within the frame of NETs, is related with fibrin arrangement. NETs, due to their adversely charged surface, start the enactment of FXII. Too, NETs, due to their capacity to tie to fibrin, repress clot debasement by blocking fibrin cleavage locales with tPA and plasminogen official. This highlight causes the improvement of microthrombotic complications amid sepsis [44]. Hence, SIC remains a challenging issue for specialists and intensivists since there are no markers to distinguish it and treatment

depends on the understanding. The method basic SIC may be a complex interconnected structure of proteases from both the coagulation and fiery cascades, which clarifies the complexity of treatment [43,44,46]. Another imperative pathogenetic component of the advancement of coagulopathy within the late period of burn damage is surgical treatment of patients. Intraoperative blood misfortune is a vital issue in burn surgery. Patients with serious burn damage involvement intraoperative consumption of coagulation components, fibrinogen and platelets, which leads to the improvement of coagulopathy [28,31,44,55]. At the same time, the require for blood transfusion is related with exacerbation of the course of coagulopathy [55,56,57]. Seriously treatment, particularly effective implantation treatment, moreover has an affect on the hemostatic framework. From the over it is clear that an entirety complex of unused variables is included to the progressing affect of pathogenetic variables of OIC, which exasperates the awkwardness within the hemostatic framework and leads to an alter within the characteristics of coagulopathy. The taking after changes happen at the level of components of the hemostatic framework. State of the procoagulant framework within the late post-burn period After burn stun, numerous considers demonstrate an increase in platelet levels [28,31]. TAK and FVII action remains lifted for a week after burn harm, showing hypercoagulability [28]. The action of FVIII as an intense stage specialist is expanded within the first days after warm harm, amid surgical treatment, while the movement of FII and FX is decreased [28,31]. Fibrinogen levels peak during the primary week after burn harm and stay lifted, but within the postoperative period there's a diminish in fibrinogen levels due to blood misfortune [28,52]. State of the anticoagulant framework in the late post-burn period AT action diminishes after warm harm, and the level of diminishment in AT connects with the seriousness of the damage and antagonistic results [28,35]. Within the perioperative period, AT action diminishes indeed more. PC and PS levels tend to diminish within the to begin with days after burn damage [35,59]. The level of solvent HMs usually increments after 48 hours and remains lifted for 7 days after burn damage [28]. In expansion, solvent HM levels in people have been appeared to be closely related with expanded TNF-α levels after burn damage, recommending that TNF-α fortifies HM generation [54]. Fibrinolytic framework within the late post-burn period tPA levels after burn stun gradually normalize after a sharp increment inside 24 hours after burn damage. Increments in PAI-1 and D-dimer levels are too watched [28,60].

Plasminogen levels gradually increase, after decreasing in the acute period to normal or near-normal physiological levels by the 5th day after the burn. There is a correlation between plasminogen levels and the severity of thermal injury [14]. The relationship between plasminogen levels and the severity of thermal injury may illustrate a dose-dependent activation of fibrinolytic activity: more severe burns lead to greater fibrinolysis and decreased plasminogen levels [31,61]. Thus, late complications associated with burns, such as sepsis and bleeding caused by surgical treatment, can also cause coagulopathy and may affect coagulation. Normalization of fibrinolytic factors appears to be associated with survival, although these data remain to be studied [44].

5. Conclusions

In conclusion, the discussion of results in the bibliographic review provides critical insights into the methods used in modeling experimental coagulopathy, highlighting current practices, challenges, and opportunities for further research and clinical translation.

In general, the current understanding of coagulopathy in patients with serious warm harm recommends that changes in components of the coagulation, fibrinolytic, and provocative frameworks lead to utilitarian changes in clot elements after burn harm. These changes vary altogether from those watched with traumatic coagulopathy. Be that as it may, centering as it were on changes within the levels of these markers may lead to wrong conclusions around coagulation flow and may in this manner result in missed openings to identify (and anticipate or treat) thrombotic or hemorrhagic complications. Endeavors to capture these changes utilizing ordinary coagulation tests (PT, aPTT, platelet number) have been for the most part inadequately to characterize the coagulopathies of burn malady. Investigate and advancement of modern innovations proceeds for the forecast, determination and anticipation of these coagulopathies, making clinical choices, such as adjustment of seriously care, preoperative planning and postoperative administration of patients. The clinical importance and approaches to the avoidance and treatment of coagulopathies in burn malady proceed to be talked about. Patients with serious burns confront various challenges on the street to recuperation. After beginning treatment and revival, these patients confront delayed healing center remains, different surgeries, expanded chance of disease and sepsis, and different psychosocial obstructions. The expansion of progressed or unrecognized coagulopathy may encourage complicate this pathway and lead to negative results. By expecting and taking activity some time recently or instantly after the start of OIC, clinicians can optimize the care of their patients through dependable triage and focused on mediations.

REFERENCES

[1] N. Baeshko, A.A. Risk factors for deep vein thrombosis of the lower extremities / A.A. Baeshko // Angiology today. 2002. - No. 9. - pp. 9-14 (in Russian).

[2] Baluda, V.P. Prethrombotic state. Thrombosis and its prevention / V.P. Baluda, M.V. Baluda, A.P. Goldberg. M.-Amsterdam: Zerkalo-M, 1999.-pp. 298 (in Russian).

[3] Voskoboy, I.V. Increased level of platelet aggregation induced by an activating antibody against glycoproteins IIb-IIIa in patients with acute coronary syndrome / I.V.

Voskoboy, A.V. Mazurov // Cardiology. 2004. - No. 10. - pp.64-70 (in Russian).

[4] Dmitriev, V.V. Practical coagulology / V.V. Dmitriev. — Minsk: Bel. Science, 2004. pp.544 (in Russian).

[5] Zubairov, D.M. Blood clotting vitamin / D.M. Zubairov // Sorosovsky images, journal. 2001. - T.7, No. 9. - pp.9-13 (in Russian).

[6] Ivanenko, I.L. Diagnostic significance of studying the hemostasis system in cancer patients / I.L. Ivanenko, G.P. Gladilin, S.I. Veretennikov // Thrombosis, hemostasis and rheology. - 2005. No. 4 (24). - pp.75-78 (in Russian).

[7] Kirichuk, V.F. Changes in microcirculatory hemostasis and blood rheology in diabetes mellitus / V.F. Kirichuk, N.V. Bolotova, N.V. Nikolaeva // Thrombosis, hemostasis and rheology. - 2004. No. 4(20). — pp. 12-19 (in Russian).

[8] Lisitsyna, T.A. The relationship between disease activity and the incidence of thrombosis in systemic lupus erythematosus / T.A. Lisitsyna, T.L. Tikhonova, I.E. Shirokova // Thrombosis, hemostasis and rheology. — 2005. -№2(22). pp. 55-60 (in Russian).

[9] Bergqvist, D. Venous thromboembolism and cancer: prevention of VTE / D. Bergqvist // Thromb. Res. -2001. Vol. 102, №6. - pp. 209-213 (in Russian).

[10] Bhatt, D.L. Scietific and therapeutic advances in antiplatelet therapy / D.L. Bhatt // Nature Rev. 2003. - Vol.2, №1. - pp. 15-28.

[11] Fitzgerald, L.A. Hemostasis and Thrombosis: Basic Principles and Clinical Practice / L.A. Fitzgerald, D.R. Phillips; eds.: R.W. Colman et al. Philadelphia, 1997.-P. 572-593.

[12] Gerotziafas, G.T. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-theatening hemorrhage / G.T. Gerotziafas, C. Zervas, G. Gavrielidis // Am. J. Hematol. 2002. - Vol.69. - P. 219222.

[13] Hockin, M.F. A model for the stoichiometric regulation of blood coagulation / M. F. Hockin, K. C. Jones, S.J. Evers // J. Biol. Chem. 2002. - Vol. 277. -P. 18322-18333.

[14] Man-Chiu Poon Management of thrombocytopenic bleeding: is there a role for recombinant coagylation factor Vila? / Man-Chiu Poon // Current Hematology Reports. 2003. - Vol.2. - P. 139-147.

[15] Greenhalgh D. Management of Burns. N. Engl. J. Med. 2019; 380(24): 2349–2359. doi: 10.1056/NEJMra1807442.

[16] The World Health Organization. Burns. Newsletter №365. April 2014. Available at: http://www.who.int/mediacentre/factsheets/fs365/ru (in Russian).

[17] Zhylinski Y., Gubicheva A., Skakun P. The scale of diagnostics of sepsis in patients with severe thermal injury. Emergency medicine. 2017; 6(4): 485–495. (in Russian)

[18] Alexseev A., Tyurnikov Yu. Statistical indicators of the work of burn hospitals in the Russian Federation for 2009. Combustiology. 2011; 44. Available at: http://combustiolog.ru/journal/statisticheskie-pokazateli-raboty-ozhogovy-h-statsionarov-rossijskoj-federatsii-za-2009-god (in Russian).

[19] Kondrashova D., Yeliseyeva Ye., Geltser B. Substantiation of pharmaceutical therapy protocols in patients with burns. Problems Of Standardization In Healthcare. 2011:1–2:8–12. (in Russian)

[20] Page M.J., McKenzie J.E., Bossuyt P.M. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med. 2021; 18(3). Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007028.

[21] Nielson C.B., Duethman N.C., Howard J.M. Burns: Pathophysiology of Systemic Complications and Current Management. J. Burn Care Res. 2017; 38(1): 469–481. doi: 10.1097/BCR.0000000000000355.

[22] Veeravagu A., Yoon B.C., Jiang B. National Trends in Burn and Inhalation Injury in Burn Patients: Results of Analysis of the Nationwide Inpatient Sample Database. J. Burn Care Res. 2015; 36(2): 258–265. doi: 10.1097/BCR.0000000000000064.

[23] Obukhova E. Technological Justification Of The Cost Of Treatment Of Thermal Injuries. Astrakhan Medical Journal. 2010; 5(4): 137–141. (in Russian)

[24] Williams F.N., Herndon D.N. Metabolic and Endocrine Considerations After Burn Injury. Clin. Plast. Surg. 2017: 44(3): 541–553. doi: 10.1016/j. cps.2017.02.013.

[25] Savelev V., Kirienko A. Clinical surgery: a national guide. Moscow: GEOTAR-Media. 2008; I: 864. (in Russian)

[26] Glas G.J., Levi M., Schultz M.J. Coagulopathy and Its Management in Patients With Severe Burns. J. Thromb. Haemost. 2016; 14(5): 865–74. doi: 10.1111/jth.13283.

[27] Marsden N.J., Van M., Dean S. Measuring Coagulation in Burns: An Evidence-Based Systematic Review. Scars Burn Heal. 2016; 3. doi: 10.1177/2059513117728201.

[28] Ball R.L., Keyloun J.W., Brummel-Ziedins K. Burn-Induced Coagulopathies: a Comprehensive Review. Shock. 2020; 54(2): 154–167.

[29] Kubyshkin A., Pylaeva N., Fomochkina I. Trauma, hemostasis and disseminated intravascular coagulation syndrome: pathogenic mechanisms of coagulation disorders. Clinical pathophysiology. 2016; 4: 104–117. (in Russian)

[30] Volkova S., Borovkov N. Fundamentals of clinical hematology: Textbook. N. Novgorod: Publishing House, Nizhny Novgorod State Medical Academy. 2013:400. (in Russian)

[31] Borisov V., Ermolov A. Coagulopathy in patients with severe burns (review). Transfusiology. 2019; 20(1): 38–48. (in Russian)

[32] Jackson S.P., Darbousset R., Schoenwaelder S.M. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019; 133(9): 906–918.

[33] Jeschke M.G., van Baar M.E., Choudhry M.A. Burn injury Nat. Rev. Dis. Primers. 2020; 6(1): 11. doi: 10.1038/s41572-020-0145-5.

[34] Standl T., Annecke T., Cascorbi I. The Nomenclature, Definition and Distinction of Types of Shock. Dtsch. Arztebl. Int. 2018; 115(45): 757–768. Published online 2018 Nov 9. doi: 10.3238/arztebl.2018.0757.

[35] Lavrentieva A., Kontakiotis T., Bitzani M. Early coagulation disorders after every burn injury: impact on mortality. In. Care Med. 2008; 34(4): 700– 706. doi: 10.1007/s00134-007-0976-5.

[36] Marsden N.J., Lawrence M., Davies N. The effect of the acute inflammatory response of burns and its treatment on clot characteristics and quality: A prospective case controlled study. Burns. 2020; 46(5): 1051–1059. doi: 10.1016/j.burns.2019.11.008.

[37] Geng K., Liu Y., Yang Y. Incidence and Prognostic Value of Acute Coagulopathy After Extensive Severe Burns. J. Burn Care Res. 2020; 41(3): 544–549. doi: 10.1093/jbcr/irz178.

[38] Keyloun J.W., Le T.D., Pusateri A.E. Circulating Syndecan-1 and Tissue Factor Pathway Inhibitor, Biomarkers of Endothelial Dysfunction, Predict Mortality in Burn Patients. Shock. 2021; 56(2): 237–244. doi: 10.1097/SHK.0000000000001709.

[39] Kaita Y., Nishimura H., Tanaka Y. Effect of acute coagulopathy before fluid administration in mortality for burned patients. Burns. 2021; 47(4): 805–811. doi: 10.1016/j.burns.2020.10.011.

[40] Ma Q.M., Liu X.B., Wu G.S. Retrospective cohort study on the coagulation characteristics of adult patients with extensively severe burn in shock stage and its alarming value. Zhonghua Shao Shang Za Zhi. 2021; 37(2): 150–156. (in Chin.)

[41] Lippi G., Ippolito L., Cervellin G. Disseminated intravascular coagulation in burn injury. Semin. Thromb. Hemost. 2010; 36(4): 429–436.

[42] Gibson B.H.Y., Wollenman C.C, Moore-Lotridge S.N. Plasmin drives burn-induced systemic inflammatory response syndrome. JCI Insight. 2021; 6(23): e154439. doi: 10.1172/jci.insight.154439.

[43] Tejiram S., Brummel-Ziedins K.E., Orfeo T. In-depth analysis of clotting dynamics in burn patients. J. Surg. Res. 2016; 202(2): 341–51. doi: 10.1016/j. jss.2016.01.006.

[44] Xiao K., Zhao W., Liao X. Early correction of coagulopathy reduces the 28-day mortality in adult patients with large-area burns. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021; 46(8): 851–857. doi: 10.11817/j.issn.1672-7347.2021.190817.

[45] Hofstra J.J., Vlaar A.P., Knape P. Pulmonary activation of coagulation and inhibition of fibrinolysis after burn injuries and inhalation trauma. J. Trauma. 2011; 70(6): 1389–1397. doi: 10.1097/TA.0b013e31820f85a7.

[46] Sommerhalder C., Blears E., Morton A.J. Current Problems in Burn Hypermetabolism. Curr. Probl. Surg. 2020; 57(1): 100709. doi: 10.1016/j. cpsurg.2019.100709.

[47] Glas G.J., Levi M., Schultz M.J. Coagulopathy and Its Management in Patients With Severe Burns. J. Thromb. Haemost. 2016; 14(5): 865–874. doi: 10.1111/jth.13283.

[48] Muthukumar V., Karki D., Jatin B. Concept of Lethal Triad in Critical Care of Severe Burn Injury. Indian J. Crit. Care Med. 2019; 23(5): 206–209. doi: 10.5005/jp-journals-10071-23161.

[49] Mitra B., Wasiak J., Cameron P.A. Early coagulopathy of major burns. Injury. 2013; 44(1): 40–43. doi: 10.1016/j.injury.2012.05.010.

[50] Sherren P.B., Hussey J., Martin R. Lethal triad in severe burns. Burns. 2014; 40(8): 1492–6. doi: 10.1016/j.burns.2014.04.011.

[51] Lawrence C., Atac B. Hematologic changes in massive burn injury. Crit. Care Med. 1992; 20(9): 1284–1288. doi: 10.1097/00003246-199209000- 00015.

[52] Brohi K., Cohen M.J., Ganter M.T. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J. Trauma. 2008; 64(5): 1211–1217. doi: 10.1097/TA.0b013e318169cd3c.

[53] Tejiram S., Brummel-Ziedins K.E., Orfeo T. In-depth analysis of clotting dynamics in burn patients. J Surg. Res. 2016; 202(2): 341–351. doi: 10.1016/ j.jss.2016.01.006.

[54] Pusateri A.E., Le T.D., Keyloun J.W. Early abnormal fibrinolysis and mortality in patients with thermal injury: a prospective cohort study. BJS Open. 2021; 5(2). doi: 10.1093/bjsopen/zrab017.

[55] Huzar T.F., Martinez E., Love J. Admission Rapid Thrombelastography (rTEG) Values Predict Resuscitation Volumes and Patient Outcomes After Thermal Injury. J. Burn Care Res. 2018; 39(3): 345–352. doi: 10.1097/BCR.0000000000000593.

[56] Pidcoke H.F., Isabella C.L., Herzig M.C. Acute blood loss during burn and soft tissue excisions: An observational study of blood product resuscitation practices and focused review. J. Trauma Acute Care Surg. 2015; 78(6 Suppl. 1): 39–47. doi: 10.1097/TA.0000000000000627.

[57] Welling H., Ostrovsky C.S., Stensballe J. Management of bleeding in major burn surgery. Burns. 2019; 45(4): 755–762. doi: 10.1016/ j.burns.2018.08.024. Epub 2018 Oct 3.

[58] Palmieri T.L. Burn injury and blood transfusion. Curr Opin Anaesthesiol. 2019; 32(2): 247–251. doi: 10.1097/ACO.0000000000000701.

[59] Wiegele M., Schaden E., Koch S. Thrombin generation in patients with severe thermal injury. Burns. 2019; 45(1): 54–62. doi: 10.1016/ j.burns.2018.09.020

[60] King D.R., Namias N., Andrews D.M. Coagulation abnormalities following thermal injury. Blood Coagul Fibrinolysis. 2010; 21(7): 666–669. doi: 10.1097/MBC.0b013e32833ceb08.

[61] Nakae H., Endo S., Inada K. Plasma levels of endothelin-1 and thrombomodulin in burn patients. Burns. 1996; 22(8): 594–597. doi: 10.1016/s0305- 4179(96)00063-0.